Psoriasis–AD Switching May Mimic Treatment Failure
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
By
Andrea Surnit
June 15, 2026
Clinical Scorecard: Psoriasis–AD Switching May Mimic Treatment Failure
At a Glance
Category Detail
Condition Psoriasis and Atopic Dermatitis Key Mechanisms Persistent, treatment-associated phenotype switching between psoriasis and atopic dermatitis due to immune rebalancing. Target Population Patients with psoriasis or atopic dermatitis undergoing systemic or biologic therapy. Care Setting Multicenter dermatology clinics across multiple countries.
Key Highlights
101 patients developed eczematous features while treated for psoriasis. 47 patients developed psoriasiform disease while treated for atopic dermatitis. Switching often occurred during treatment with interleukin-17 or interleukin-23 inhibitors. Janus kinase inhibitors were the most frequently documented management strategy. Clinical severity scores improved following therapeutic adjustment. Guideline-Based Recommendations
Diagnosis
Sustained phenotype switching should be considered when patients develop opposing features. Management
Therapeutic adaptation may include broader immunomodulatory approaches such as Janus kinase inhibition. Monitoring & Follow-up
Clinical severity scores should be monitored following treatment modification. Risks
Potential misclassification of treatment failure if phenotype switching is not recognized. Patient & Prescribing Data
Patients with psoriasis or atopic dermatitis experiencing phenotype switching.
60% of patients with psoriasis-to-eczematous switching were switched to a Janus kinase inhibitor.
Clinical Best Practices
Recognize sustained phenotype switching to avoid misclassifying treatment failure. Consider patient history and comorbidities when managing treatment. Related Resources & Content
